LitCovid-sentences  

PMC:7405836 / 113185-117879 JSONTXT 10 Projects

Annnotations TAB TSV DIC JSON TextAE

Id Subject Object Predicate Lexical cue
T770 0-41 Sentence denotes Passive Immunization/Antibody Therapy/MAb
T771 42-144 Sentence denotes Monoclonal antibodies (MAbs) may be helpful in the intervention of disease in CoV-exposed individuals.
T772 145-246 Sentence denotes Patients recovering from SARS showed robust neutralizing antibodies against this CoV infection (164).
T773 247-485 Sentence denotes A set of MAbs aimed at the MERS-CoV S protein-specific domains, comprising six specific epitope groups interacting with receptor-binding, membrane fusion, and sialic acid-binding sites, make up crucial entry tasks of S protein (198, 199).
T774 486-638 Sentence denotes Passive immunization employing weaker and strongly neutralizing antibodies provided considerable protection in mice against a MERS-CoV lethal challenge.
T775 639-809 Sentence denotes Such antibodies may play a crucial role in enhancing protective humoral responses against the emerging CoVs by aiming appropriate epitopes and functions of the S protein.
T776 810-1172 Sentence denotes The cross-neutralization ability of SARS-CoV RBD-specific neutralizing MAbs considerably relies on the resemblance between their RBDs; therefore, SARS-CoV RBD-specific antibodies could cross-neutralized SL CoVs, i.e., bat-SL-CoV strain WIV1 (RBD with eight amino acid differences from SARS-CoV) but not bat-SL-CoV strain SHC014 (24 amino acid differences) (200).
T777 1173-1438 Sentence denotes Appropriate RBD-specific MAbs can be recognized by a relative analysis of RBD of SARS-CoV-2 to that of SARS-CoV, and cross-neutralizing SARS-CoV RBD-specific MAbs could be explored for their effectiveness against COVID-19 and further need to be assessed clinically.
T778 1439-1551 Sentence denotes The U.S. biotechnology company Regeneron is attempting to recognize potent and specific MAbs to combat COVID-19.
T779 1552-1702 Sentence denotes An ideal therapeutic option suggested for SARS-CoV-2 (COVID-19) is the combination therapy comprised of MAbs and the drug remdesivir (COVID-19) (201).
T780 1703-1858 Sentence denotes The SARS-CoV-specific human MAb CR3022 is found to bind with SARS-CoV-2 RBD, indicating its potential as a therapeutic agent in the management of COVID-19.
T781 1859-1994 Sentence denotes It can be used alone or in combination with other effective neutralizing antibodies for the treatment and prevention of COVID-19 (202).
T782 1995-2257 Sentence denotes Furthermore, SARS-CoV-specific neutralizing antibodies, like m396 and CR3014, failed to bind the S protein of SARS-CoV-2, indicating that a particular level of similarity is mandatory between the RBDs of SARS-CoV and SARS-CoV-2 for the cross-reactivity to occur.
T783 2258-2354 Sentence denotes Further assessment is necessary before confirming the effectiveness of such combination therapy.
T784 2355-2504 Sentence denotes In addition, to prevent further community and nosocomial spread of COVID-19, the postprocedure risk management program should not be neglected (309).
T785 2505-2715 Sentence denotes Development of broad-spectrum inhibitors against the human coronaviral pathogens will help to facilitate clinical trials on the effectiveness of such inhibitors against endemic and emerging coronaviruses (203).
T786 2716-2876 Sentence denotes A promising animal study revealed the protective effect of passive immunotherapy with immune serum from MERS-immune camels on mice infected with MERS-CoV (204).
T787 2877-3024 Sentence denotes Passive immunotherapy using convalescent plasma is another strategy that can be used for treating COVID-19-infected, critically ill patients (205).
T788 3025-3379 Sentence denotes The exploration of fully human antibodies (human single-chain antibodies; HuscFvs) or humanized nanobodies (single-domain antibodies; sdAb, VH/VHH) could aid in blocking virus replication, as these agents can traverse the virus-infected cell membranes (transbodies) and can interfere with the biological characteristics of the replicating virus proteins.
T789 3380-3493 Sentence denotes Such examples include transbodies to the influenza virus, hepatitis C virus, Ebola virus, and dengue virus (206).
T790 3494-3891 Sentence denotes Producing similar transbodies against intracellular proteins of coronaviruses, such as papain-like proteases (PLpro), cysteine-like protease (3CLpro), or other nsps, which are essential for replication and transcription of the virus, might formulate a practical move forward for a safer and potent passive immunization approach for virus-exposed persons and rendering therapy to infected patients.
T791 3892-4085 Sentence denotes In a case study on five grimly sick patients having symptoms of severe pneumonia due to COVID-19, convalescent plasma administration was found to be helpful in patients recovering successfully.
T792 4086-4389 Sentence denotes The convalescent plasma containing a SARS-CoV-2-specific ELISA (serum) antibody titer higher than 1:1,000 and neutralizing antibody titer more significant than 40 was collected from the recovered patients and used for plasma transfusion twice in a volume of 200 to 250 ml on the day of collection (310).
T793 4390-4507 Sentence denotes At present, treatment for sepsis and ARDS mainly involves antimicrobial therapy, source control, and supportive care.
T794 4508-4617 Sentence denotes Hence, the use of therapeutic plasma exchange can be considered an option in managing such severe conditions.
T795 4618-4694 Sentence denotes Further randomized trials can be designed to investigate its efficacy (311).